Phase II Temozolomide + Vorinostat in Patients (>60) w/ Newly Diagnosed or Relapse/Refractory AML
This study is not yet open for participant recruitment.
Verified February 2013 by Stanford University
Sponsor:
Stanford University
Collaborator:
Merck
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01550224
First received: March 7, 2012
Last updated: February 13, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is not yet open for participant recruitment. |
|---|---|
| Estimated Study Completion Date: | April 2016 |
| Estimated Primary Completion Date: | April 2015 (Final data collection date for primary outcome measure) |